-+ 0.00%
-+ 0.00%
-+ 0.00%

IGC Pharma Granted Patent From USPTO For Propriety Formulation Used In IGC-AD1 Drug Candidate For Agitation In Alzheimer's Disease

Benzinga·11/13/2025 14:04:42
Listen to the news

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced that the United States Patent and Trademark Office ("USPTO") has granted the company U.S. Patent No. 12,465,589, titled "Methods and Composition for Treating CNS Disorders." The patent covers the propriety formulation used in IGC-AD1, the Company's lead drug candidate currently being evaluated in the Phase 2 CALMA (Clinically Advanced Lead Molecule for Agitation) trial for agitation in Alzheimer's disease.

The patent granted on November 11, 2025, covers a proprietary composition for treating Alzheimer's disease including amyloid plaque, tau tangles as well as symptoms associated with Alzheimer's, such as agitation, memory, cognition, anxiety, and sleep disturbances.